MicroSigX Awarded RAISe+ Funding to Advance First-in-Class Microbiome Diagnostics for IBD and ASD
We’re proud to share that MicroSigX Biotech Diagnostic Limited, a spin-off from The Chinese University of Hong Kong (CUHK), has been awarded funding under the prestigious RAISe+ Scheme by the Innovation and Technology Commission (ITC) of the Hong Kong government.
Our funded project, TRANSFORMX, is set to redefine non-invasive diagnostics for two of the world’s most pressing health challenges: Inflammatory Bowel Disease (IBD) and Autism Spectrum Disorder (ASD).
Led by world-renowned clinician-scientists Professors Siew Ng and Francis Chan, TRANSFORMX introduces two breakthrough technologies: Enterosight – a stool-based PCR assay for IBD, delivering >90% cost savings compared to colonoscopy, and MSX MetaGenie – the first stool-based ASD diagnostic to receive FDA Breakthrough Device Designation, powered by AI-driven metagenomics.
Backed by publications in Nature Medicine and Nature Microbiology, and validated across multi-ethnic cohorts, these innovations are clinically proven, scalable, and globally relevant.
With a seasoned leadership team including CEO Rachel Fan and Finance & Operations Director Deric Ho, MicroSigX is on a clear path from research to commercialisation, with collaboration across government, industry and academia. We aim to launch the two new innovations in Hong Kong by 2027, with plans for FDA and NMPA regulatory approval.
This milestone marks the development of the first microbiome-based diagnostic test fully developed in Hong Kong, reinforcing the city’s position as a rising leader in the global microbiome industry.
https://lnkd.in/gV_aa3-c
#MicroSigX
#RAISePlus
#MicrobiomeDiagnostics
#IBD
#ASD
#Innovation
#HealthcareInvesting
#CUHK
#HongKongInnovation
#Biotech
#FDA
#GlobalHealth
GenieBiome Limited 精進微生物科技有限公司
Microbiota I-Center (MagIC) (香港微生物菌群創新中心)
CUHK Medicine
